WaveMan
WaveMan · Company
ACUT · Accustem Sciences Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

ACUT Accustem Sciences (ACUT) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001850767
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter

Accustem Sciences insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Accustem Sciences Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
CERRONE GABRIELE M
Director
BUY
2025-06-16 SECtraded 2025-06-13
2,000
$2.0K
-86.9%
Context
  • 15 earlier Form 4 trades (code P or S) here by this insider (15 buys), the last on Jun 12, 2025.
  • +15.3% median (+37.6% mean) 90-day return after 14 previous buys.
  • The trade is 0.0% of the 6,502,000 shares held after it.
  • No other insider bought within 30 days.
Insider activity: Director CERRONE GABRIELE M bought about $2.0K of ACUT on Jun 13, 2025.
CERRONE GABRIELE M
Director
BUY
2025-06-16 SECtraded 2025-06-13
400
$440
-86.9%
Context
  • 15 earlier Form 4 trades (code P or S) here by this insider (15 buys), the last on Jun 12, 2025.
  • +15.3% median (+37.6% mean) 90-day return after 14 previous buys.
  • The trade is 0.0% of the 6,502,400 shares held after it.
  • No other insider bought within 30 days.
Insider activity: Director CERRONE GABRIELE M bought about $440 of ACUT on Jun 13, 2025.
CERRONE GABRIELE M
Director
BUY
2025-06-13 SECtraded 2025-06-12
8,991
$7.5K
-86.8%
Context
  • 14 earlier Form 4 trades (code P or S) here by this insider (14 buys), the last on Jun 11, 2025.
  • +14.6% median (+33.9% mean) 90-day return after 13 previous buys.
  • The trade is 0.1% of the 6,500,000 shares held after it.
  • No other insider bought within 30 days.
Insider activity: Director CERRONE GABRIELE M bought about $7.5K of ACUT on Jun 12, 2025.
CERRONE GABRIELE M
Director
BUY
2025-06-13 SECtraded 2025-06-11
28,205
$11.0K
-86.8%
Context
  • 13 earlier Form 4 trades (code P or S) here by this insider (13 buys), the last on Apr 9, 2025.
  • +13.9% median (+20.8% mean) 90-day return after 12 previous buys.
  • The trade is 0.4% of the 6,491,009 shares held after it.
  • No other insider bought within 30 days.
Insider activity: Director CERRONE GABRIELE M bought about $11.0K of ACUT on Jun 11, 2025.
CERRONE GABRIELE M
Director
BUY
2025-04-10 SECtraded 2025-04-09
3,000
$2.0K
-70.4%
Context
  • 12 earlier Form 4 trades (code P or S) here by this insider (12 buys), the last on Apr 8, 2025.
  • +13.2% median (+11.8% mean) 90-day return after 11 previous buys.
  • The trade is 0.1% of the 4,910,759 shares held after it.
  • No other insider bought within 30 days.
Insider activity: Director CERRONE GABRIELE M bought about $2.0K of ACUT on Apr 9, 2025.
17 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 12 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
<0.1% of the float short (float per yahoo 2026-10-26) · 8.2 days to cover · settled 2026-09-30
below 93% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch ACUT

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-89.4%12M
-91%-58%-26%+6%2025-102025-122026-022026-042026-062026-082026-10
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ACUT: institutional holders (13F)

13F holdings, latest reported quarter
SEC 13F
No reported 13F holders

No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.

Congress trades in ACUT

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ACUT planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
Each figure here is a federal filing, dated the day it went public, so you can test what was knowable then.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

ACUT financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$1.2M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
n/a
average equity is zero or negative
Return on assets
-102.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
n/a
capital employed is zero or negative
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-56.6%
TTM free cash flow over market value at close 2026-10-23
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$1.8M-$1.5M-$2.1M-$3.7M
Net income-$1.8M-$1.5M-$2.1M-$3.7M
EPS (diluted)-0.12-0.13-0.18-0.34
Operating cash flow-$850.4K-$664.1K-$1.6M-$1.8M
SEC XBRL, fiscal years, as known on 2026-10-27

ACUT Stock Sonar score 1/7 axes

Find similar shapesCompare
Risk and compliance
97
Inputs
  • Short interest, % of float+0.0% · 95 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+0.1% · 100 pct, sector of 511
6 not measured: Profitability, Financial health, Growth, Insider conviction, Institutional and government, US patents
  • Profitability needs 2 of 4 inputs, 1 present: average equity is zero or negative; capital employed is zero or negative; tax provision or pre-tax income not filed for the four quarters
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

1 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies